Source:http://linkedlifedata.com/resource/pubmed/id/11019837
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2000-12-26
|
| pubmed:abstractText |
We studied the effect of the CD34+ cell dose on transplant-related mortality (TRM) and survival in 39 patients randomized to receive lenograstim-mobilized PBSCT (n = 20) or BMT (n = 19) from HLA-identical siblings. Both marrow and blood were harvested, and one infused in a double-blind fashion. The median nucleated (7.0 vs 3.2 x 10(8)/kg; P < 0.0001), CD34+ (3.7 vs 1.5 x 10(6)/kg; P = 0.002), CFU-GM (42 vs 19 x 10(4)/kg; P = 0.002), and CD3+ (1.9 vs 0.3 x 10(8)/kg; P < 0.0001) cell doses with PBSCT were higher. Thirteen patients (6 BMT and 7 PBSCT) experienced TRM at 15-733 days (median 57); 10 of 20 receiving <2 x 10(6) CD34+ cells/kg compared with three of 19 receiving > or =2. Eight of 20 patients receiving <2 x 10(6) CD34+ cells/kg are alive compared with 14 of 19 receiving > or =2. In Cox analysis, CD34+ cell dose > or =2 x 10(6)/kg was associated with lower TRM (RR 0.2, P = 0.01), and higher overall (RR 3.7, P = 0.01) and event-free (RR 3.2, P = 0.02) survival. Other cell populations and the source of stem cells did not affect TRM or survival. We conclude that 2 x 10(6) CD34+ cells/kg may be the ideal minimum cell dose for allogeneic transplantation although lower doses do not preclude successful therapy. Since the likelihood of obtaining this threshold CD34+ cell number is significantly greater from blood than marrow, PBSCT may be preferable to marrow for allografts from HLA-identical siblings.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:HortonCC,
pubmed-author:KulkarniSS,
pubmed-author:MehtaJJ,
pubmed-author:MillarBB,
pubmed-author:NollJ DJD,
pubmed-author:PowlesRR,
pubmed-author:RowlandAA,
pubmed-author:SasoRR,
pubmed-author:ShepherdVV,
pubmed-author:SinghalSS,
pubmed-author:SirohiBB,
pubmed-author:TaitDD,
pubmed-author:TreleavenJJ
|
| pubmed:issnType |
Print
|
| pubmed:volume |
26
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
489-96
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11019837-Adolescent,
pubmed-meshheading:11019837-Adult,
pubmed-meshheading:11019837-Antigens, CD3,
pubmed-meshheading:11019837-Antigens, CD34,
pubmed-meshheading:11019837-Bone Marrow Transplantation,
pubmed-meshheading:11019837-Cell Count,
pubmed-meshheading:11019837-Double-Blind Method,
pubmed-meshheading:11019837-Female,
pubmed-meshheading:11019837-Follow-Up Studies,
pubmed-meshheading:11019837-Graft vs Host Disease,
pubmed-meshheading:11019837-Hematologic Neoplasms,
pubmed-meshheading:11019837-Hematopoiesis,
pubmed-meshheading:11019837-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11019837-Hematopoietic Stem Cells,
pubmed-meshheading:11019837-Histocompatibility,
pubmed-meshheading:11019837-Humans,
pubmed-meshheading:11019837-Male,
pubmed-meshheading:11019837-Middle Aged,
pubmed-meshheading:11019837-Multivariate Analysis,
pubmed-meshheading:11019837-Nuclear Family,
pubmed-meshheading:11019837-Survival Rate,
pubmed-meshheading:11019837-Transplantation, Homologous,
pubmed-meshheading:11019837-Transplantation, Isogeneic
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold?
|
| pubmed:affiliation |
Leukaemia Unit, Royal Marsden Hospital, Surrey, UK.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|